Morote J - Search Results

1

Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).

Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA. Ribas A, et al. Among authors: morote j. Tumori. 1996 Nov-Dec;82(6):554-9. doi: 10.1177/030089169608200608. Tumori. 1996. PMID: 9061063

2

[Clinical course of hormone refractory cancer of the prostate].

Morote J, Vila J, López-Pacios MA, De Torres JA, Soler-Roselló A. Morote J, et al. Actas Urol Esp. 1992 Oct;16(9):722-5. Actas Urol Esp. 1992. PMID: 1283286 Spanish.

3

[Can we do without bone gammagraphy in the staging of prostatic cancer?].

Morote J, Olona M, Villa J, Reig C, López MA, de Torres JA, Soler A. Morote J, et al. Actas Urol Esp. 1992 Jun;16(6):487-9; discussion 489-90. Actas Urol Esp. 1992. PMID: 1509919 Spanish.

4

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.

Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA. Bellmunt J, et al. Among authors: morote j. Cancer. 1992 Oct 1;70(7):1974-9. doi: 10.1002/1097-0142(19921001)70:7<1974::aid-cncr2820700727>3.0.co;2-d. Cancer. 1992. PMID: 1525774 Clinical Trial.

5

[Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].

Morote J, de Torres JA. Morote J, et al. Actas Urol Esp. 1990 Jul-Aug;14(4):268-70. Actas Urol Esp. 1990. PMID: 1702258 Spanish.

6

[Effects of transurethral resection on the serum concentration of prostate specific antigen and prostatic acid phosphatase].

Morote J, de Torres JA. Morote J, et al. Actas Urol Esp. 1990 Sep-Oct;14(5):356-7. Actas Urol Esp. 1990. PMID: 1705076 Spanish.

7

[Treatment of hormone-refractory prostate cancer with estramustine phosphate].

Morote J, López-Pacios MA, Ahmad A, Vila J, de Torres JA. Morote J, et al. Actas Urol Esp. 1991 Sep-Oct;15(5):421-4. Actas Urol Esp. 1991. PMID: 1725472 Clinical Trial. Spanish.

8

[Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms].

Morote J, López-Pacios MA, Encabo G, de Torres JA. Morote J, et al. Med Clin (Barc). 1990 Jun 16;95(3):119. Med Clin (Barc). 1990. PMID: 2123505 Spanish. No abstract available.

9

[Usefulness of the prostate-specific antigen in monitoring prostatic carcinoma. Its correlation with acid phosphatase].

Morote J, Ruibal A, de Torres JA, Palou J. Morote J, et al. Med Clin (Barc). 1986 Apr 26;86(16):695. Med Clin (Barc). 1986. PMID: 2426531 Spanish. No abstract available.

10

Bone marrow prostatic specific antigen and prostatic acid phosphatase levels: are they helpful in staging prostatic cancer?

Morote J, Ruibal A, Pascual C, Palou J, de Torres JA. Morote J, et al. J Urol. 1987 May;137(5):891-3. doi: 10.1016/s0022-5347(17)44286-8. J Urol. 1987. PMID: 2437332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters